Fishers Test Kitchen in Sun King building closes, making way for Indy chef with big name

As the restaurant development program concludes its nearly five-year run, Fishers will welcome a chef with Food Network flare ...

Two England bowling options emerge for Sydney after Atkinson injury

Two England bowling options emerge for Sydney Ashes Test after Gus Atkinson injury - Atkinson has been ruled out of the final ...
BBC

Who is Matthew Fisher and could he play in the third Test?

Matthew Fisher is a right-arm fast-medium bowler who plays for Surrey and England Lions. The 28-year-old has been added to England's Test squad for the final three Tests of the Ashes after quick Mark ...
NDTV

Updated World Test Championship Points Table After Australia Thrash England In Pink-Ball Ashes Test

Australia maintained their 100 per cent win record in the ongoing World Test Championship (WTC) after thrashing England by eight wickets in the 2nd Ashes Test in Brisbane on Sunday. Asked to chase a ...
eLife

Atovaquone/Proguanil Use and Zoster Vaccination Are Associated with Reduced Alzheimer’s Disease Risk in Two Cohorts: Implications for a Latent Toxoplasma gondii Mechanism

This useful study raises interesting questions but provides inadequate evidence of an association between atovaquone-proguanil use (as well as toxoplasmosis seropositivity) and reduced Alzheimer's ...
MarketWatch

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...
Milwaukee Journal Sentinel

Abbott to buy Madison-based Exact Sciences in deal valued at up to $23 billion

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...
Reuters

Abbott bets on cancer screening with $23 billion Exact Sciences deal

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...
Forbes

Abbott’s $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Business Wire

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ ...
Milwaukee Journal Sentinel

Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know

The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...